Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial

被引：0
|
作者：
de Wit, R. [1 ]
Kulkarni, G. S. [2 ]
Uchio, E. [3 ]
Singer, E. A. [4 ]
Krieger, L. [5 ]
Grivas, P. [6 ]
Bajorin, D. [7 ]
Seo, H. K. [8 ]
Mourey, L. [9 ]
Kamat, A. [10 ]
Nishiyama, H. [11 ]
Kapadia, E. [12 ]
Nam, K. [12 ]
Frenkl, T. [12 ]
Balar, A. [13 ]
机构：
[1] Erasmus MC, Med Oncol, Inst Canc, Rotterdam, Netherlands
[2] UHN Princess Margaret Canc Ctr, Surg & Surg Oncol, Toronto, ON, Canada
[3] UC Irvine Hlth, Urol, Orange, CA USA
[4] Rutgers Canc Inst New Jersey, Urol, New Brunswick, NJ USA
[5] Royal North Shore Hosp, Med Oncol, Northern Canc Inst, St Leonards, NSW, Australia
[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Med Oncol, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[7] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[8] Natl Canc Ctr, Urol, Goyang, South Korea
[9] Inst Univ Canc Toulouse Oncopole, Med Oncol, Toulouse, France
[10] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA
[11] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan
[12] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[13] NYU Langone Med Ctr, Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
864O
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [1] PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN
    Kulkarini, Girish S.
    de Wit, Ronald
    Balar, Arjun V.
    Kamat, Ashish
    Uchio, Edward
    Mourey, Loic
    Krieger, Laurence
    Singer, Eric A.
    Bajorin, Dean
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuku
    Konety, Badarinath
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    Boormans, Joost L.
    [J]. JOURNAL OF UROLOGY, 2019, 201 (04): : E616 - E616
  • [2] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
    Balar, Arjun Vasant
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost
    Mourey, Loic
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [5] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [7] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Gupta, S.
    Kulkarni, G.
    Necchi, A.
    Shore, N. D.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
  • [8] Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.
    De Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Krieger, Laurence Eliot Miles
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Boormans, J. L.
    Roumiguie, M.
    Krieger, L. E. M.
    Singer, E. A.
    Bajorin, D. F.
    Kamat, A. M.
    Grivas, P.
    Seo, H. K.
    Nishiyama, H.
    Konety, B. R.
    Saretsky, T.
    Li, H.
    Nam, K.
    Sbar, E.
    Balar, A. V.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
12345